Tandem Diabetes Care Inc (FRA:TD5A)
€ 46.5 -0.61 (-1.29%) Market Cap: 3.09 Bil Enterprise Value: 3.10 Bil PE Ratio: 0 PB Ratio: 13.74 GF Score: 77/100

Tandem Diabetes Care Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 16, 2020 / 03:45PM GMT
Release Date Price: €92.74 (+2.85%)
Marissa Elizabeth Bych
Morgan Stanley, Research Division - Research Associate

All right. Good morning, and welcome. This is Marissa Bych from Morgan Stanley Equity Research. I work with David Lewis in Medical Devices. I'm very excited this morning to have John Sheridan, the CEO; and Leigh Vosseller, the CFO of Tandem Diabetes with me this morning. And Leigh and John, I hosted you both last year in-person, more fortunately, but we have the opportunity to talk a little bit about the Basal-IQ success that you had, had. And obviously, now we get to talk more about Control-IQ's success.

So let's maybe start off with some of the nearer-term dynamics and then work into product specifics and what you have in the pipeline catalysts ahead. But it's great to have you both here.

Questions & Answers

Marissa Elizabeth Bych
Morgan Stanley, Research Division - Research Associate

The first thing I want to talk about is just that there were a lot of moving factors in your recent results, right? So Control-IQ momentum most clearly. And COVID-19, obviously,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot